Allergic Skin Reaction, Biotherapy, Chronic Inflammatory Disease, Dermatologic Complication, Gastrointestinal Disease, Ophthalmology, Pediatric Disorder, Rheumatology
Conditions
Keywords
Biotherapy, Chronic Inflammatory Disease, skin adverse event, paradoxical reaction, cutaneous manifestation, pediatry, dermatology, gastro-enterology, ophthalmology, rheumatology
Brief summary
Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance or exacerbation of a pathological condition that usually responds to this class of drug while treating a patient for another condition. Limited data are available in children treated by BT on cutaneous paradoxical reactions, or any other cutaneous adverse events occurring during treatment. On the contrary, dermatologists tend to see and manage increasing numbers of cutaneous adverse events, including paradoxical reactions. The aim of this project is to describe the incidence of cutaneous adverse events, including cutaneous paradoxical reactions, occurring in the pediatric population, during a treatment by BT given for a chronic inflammatory disease.
Interventions
OTHERdermatological consultation
Dermatological consultation will be done on every children treated by biotherapy for chronic inflammatory disease in the Amiens hospital.
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
* Children under 18 years old * Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab, Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept. * Children treated for a chronic inflammatory disease (rheumatologic, gastro-enterologic, dermatologic and ophthalmologic) * Children treated in the CHU of Amiens * Parental consent signed
Exclusion criteria
* Age \> 18 ans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation of the incidence of cutaneous adverse events under biological therapy | up to 8 months | Determine the variation of the incidence of any skin manifestation under biological therapy, including Paradoxical Reaction (psoriasis, eczema, hidradenitis suppurativa …), non-paradoxical inflammatory reaction, infection, neoplasia, hair and nail manifestation, xerosis. |
Countries
France
Outcome results
None listed